Trex Bio (TRXB) closed at $14.01 on October 16, 2026, down 1.1% from the previous close, on volume of 73,239 shares (30-day average 407,525).
Data as of October 16, 2026.
Major Investor Doubles Down on TRex Bio With Bold New Stake
TipRanks (Thu, 15-Oct 10:02 PM ET)
TRexBio Announces Closing of Initial Public Offering
Globe Newswire (Tue, 13-Oct 4:47 PM ET)
Trex Bio Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
Trex Bio trades on the NASDAQ stock market under the symbol TRXB.
As of October 16, 2026, TRXB stock price declined to $14.01 with 73,239 million shares trading.
TRXB has a market cap of $267.76 million. This is considered a Small Cap stock.
TRXB support price is $13.59 and resistance is $14.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRXB shares will trade within this expected range on the day.
